Characterization of an expanded set of assays for immunomodulatory proteins using targeted mass spectrometry
JR Whiteaker, L Zhao, RM Schoenherr, D Huang… - Scientific Data, 2024 - nature.com
Immunotherapies are revolutionizing cancer care, but many patients do not achieve durable
responses and immune-related adverse events are difficult to predict. Quantifying the …
responses and immune-related adverse events are difficult to predict. Quantifying the …
Immunoproteomics: Approach to Diagnostic and Vaccine Development
VS Gomase, SP Dhamane, KR Kemkar… - Protein & Peptide …, 2024 - benthamdirect.com
The study of large protein sets (proteomics) involved in the immunological reaction is known
as immunoproteomics. The methodology of immunoproteomics plays a major role in …
as immunoproteomics. The methodology of immunoproteomics plays a major role in …
[HTML][HTML] Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Intratumoral TLR9 agonists and anti-PD-1 produce clinical responses and broad immune
activation. We conducted a single-arm study of neoadjuvant TLR9 agonist vidutolimod …
activation. We conducted a single-arm study of neoadjuvant TLR9 agonist vidutolimod …
A phase 2 study of frontline pembrolizumab in follicular lymphoma
Background The tumor microenvironment (TME), including infiltrating T‐cells, is thought to
play a major role in the pathogenesis and prognosis of follicular lymphoma (FL) and may …
play a major role in the pathogenesis and prognosis of follicular lymphoma (FL) and may …